Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amezosvatein (CRV-101) vs Shingrix for herpes zoster prevention in adults 50+
NCT05304351Phase 2Active, not recruiting
- Sponsor
- Curevo Vaccine
- Start
- Feb 2022
- Primary completion
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of amezosvatein in herpes zoster (HZ), sponsored by Curevo Vaccine. Started Feb 2022; status: active, not recruiting.
02
Drugs
amezosvatein
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05304351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304351.